REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/06/2026
Voltar para busca
Dado oficial do USPTO
MIQURE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
42
Atualização mais recente
02/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
09/04/2019
Data de registro
01/06/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/06/2021
Última transação
02/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
26
Localização do titular
AMSTERDAM, NL
Examinador
PARADEWELAI, BENJI YUEN
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
UNIQURE BIOPHARMA B.V.
uniQure IP B.V.
Representantes
Julianne Abelman ABELMAN LAW PLLC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicinal preparations for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseasesviral systemsgene therapy systemsnucleic acid delivery systemsviral vectorsnon-viral vectorsgene therapy vectorsnucleic acid delivery vectorscells transformed by viral vectorsnon-viral vectorsgene therapy vectors or nucleic acid delivery vectors; Viral systemsgene therapy systemsnucleic acid delivery systems for medical purposesmedicines for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases; Pharmaceutical preparations and substances for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases; biological preparations for use in medical and clinical gene therapynucleic acid-based therapy and cell therapy for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid-based therapygene therapycell therapygene diagnosis and gene testing; pharmaceutical preparationsvaccinesprophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapygene therapy and cell therapy for the diagnosistreatment or prevention of Central Nervous System diseasesLiver diseasesNeuromuscular diseases and Cardiovascular diseases
Classe 42
Researchproduct development and consultancy in the field of biotechnologybiologicsmedical sciencechemistry and biochemistry; Research and product development in the field of pharmaceutics
Classe 44
Gene and nucleic acid deliverygene and nucleic acid transfergene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disordersocular disordersdiseases of the nervous systemblood disordersliver disordersmuscular disordersmuscular skeletal disorderscancersinfectious diseasesinflammatory and auto-immune diseasesvascular disordersinherited disordersgenetic disorders and single gene disorders; Consultancy in the field of pharmaceutics
Publicações
Histórico de despachos e eventos da marca no USPTO.
42 publicações encontradas
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/06/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/06/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/06/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/06/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/06/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/06/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/06/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/06/2025
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
26/05/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/05/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
26/05/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/05/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/05/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/05/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/05/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/03/2021
PUBO
PUBLISHED FOR OPPOSITION
16/03/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/02/2021
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
08/02/2021
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
05/02/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/02/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
02/02/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/02/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
02/02/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/02/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
28/01/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
11/06/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/12/2019
GNSL
LETTER OF SUSPENSION E-MAILED
05/12/2019
CNSL
SUSPENSION LETTER WRITTEN
05/12/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/12/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/12/2019
ALIE
ASSIGNED TO LIE
04/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/11/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
24/06/2019
GNRT
NON-FINAL ACTION E-MAILED
24/06/2019
CNRT
NON-FINAL ACTION WRITTEN
24/06/2019
DOCK
ASSIGNED TO EXAMINER
19/06/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/04/2019
NWAP
NEW APPLICATION ENTERED
12/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MIQURE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.